Compare Amgen, Inc. (AMGN) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Snap On Incorporated — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Snap On Incorporated trades at $401.94 (market cap $20.82B). The key difference: Amgen, Inc. is far larger — about 9.4× Snap On Incorporated's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SNA | |
|---|---|---|
Market Cap | $196.12B | $20.82B |
Sector | Health | Technology |
52-Week High | $388.16 | $413.62 |
52-Week Low | $271.18 | $313.01 |
Enterprise Value | $241.41B | $20.34B |
Dividend Yield | 2.77% | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Snap-on Incorporated (SNA) trades at $401.94, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong profitability with a 19.6% net income margin and a 17.83% ROE for 2025. Recent strategic acquisitions, including Diesel Laptops for $100 million, aim to expand its heavy-duty diagnostics capabilities, while a $500 million share repurchase authorization and consistent dividends underscore shareholder returns.
The outlook is positive, supported by operational agility and steady cash flow growth, with net cash flow rising to $318 million projected for 2026. Key risks include muted revenue growth and margin pressures, as seen in the Q1 2026 earnings miss. Investor sentiment is cautiously optimistic, with 65% of analysts rating the stock a buy, but competitive and macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
